Olmesartan Dose Equivalent to Losartan 100 mg
Olmesartan 20 mg once daily is approximately equivalent to losartan 100 mg once daily for blood pressure reduction, though olmesartan demonstrates superior antihypertensive efficacy at this dose comparison.
Evidence-Based Dose Equivalency
Direct Comparative Trials
Olmesartan 20 mg once daily produces significantly greater blood pressure reductions than losartan 100 mg once daily in head-to-head randomized controlled trials 1, 2, 3.
In a large multicenter trial of 941 patients, olmesartan 40 mg achieved mean seated diastolic blood pressure (SeDBP) reductions of 9.7 mmHg compared to 7.1 mmHg with losartan 100 mg (treatment difference: -2.5 mmHg, P<0.0001), and systolic reductions of 13.6 mmHg versus 9.7 mmHg (treatment difference: -3.9 mmHg, P=0.0001) 1.
A Chinese multicenter study demonstrated that olmesartan 20-40 mg once daily produced greater SeDBP reductions than losartan 50-100 mg once daily after both 4 weeks (11.72 vs 9.23 mmHg, P=0.004) and 8 weeks (12.94 vs 11.01 mmHg, P=0.035) 2.
The responder rate (achieving blood pressure goal <140/90 mmHg) was significantly higher with olmesartan 40 mg (65.3%) compared to losartan 100 mg (52.7%) at 4 weeks (P=0.028) 2.
Practical Dosing Algorithm
For patients currently on losartan 100 mg daily:
Switch to olmesartan 20 mg once daily as the initial equivalent dose 4, 1, 3.
If additional blood pressure reduction is needed after 2-4 weeks, titrate olmesartan to 40 mg once daily (the maximum FDA-approved dose for hypertension) 5, 1.
Olmesartan demonstrates superior 24-hour blood pressure control with higher trough-to-peak ratios than losartan, providing more consistent antihypertensive effect throughout the dosing interval 2, 6.
Clinical Superiority Considerations
A 2024 network meta-analysis of 193 studies ranked olmesartan highest for reducing office systolic blood pressure (91.4% surface under cumulative ranking) and diastolic blood pressure (87.2%), while also ranking highest in safety (70.8%) 7.
Olmesartan 20 mg demonstrated significantly greater blood pressure reductions than losartan 50 mg, valsartan 80 mg, and irbesartan 150 mg at week 2 and maintained superiority through week 8 6.
Fewer patients on olmesartan required addition of hydrochlorothiazide compared to losartan after 12 weeks of monotherapy, indicating superior efficacy as monotherapy 3.
Safety Profile
The incidence of adverse events with olmesartan (10.5%) was similar to losartan (13.9%, P>0.05), with most events being mild and transient 2.
Olmesartan and telmisartan were associated with fewer adverse events than losartan in network meta-analysis 7.
Important Caveats
In patients with hepatic impairment, start olmesartan at 10 mg once daily (lower than the standard 20 mg equivalent) due to increased bioavailability 5.
For patients with possible intravascular volume depletion (e.g., on diuretics), consider starting olmesartan at 10 mg once daily rather than 20 mg 5.
The superior efficacy of olmesartan means that some patients may experience greater blood pressure reduction than expected when switching from losartan 100 mg to olmesartan 20 mg—monitor blood pressure within 2 weeks of switching 1, 2.